News of Note—Pfizer, Meridian Medical Technologies, EpiPen, saline shortage

Newspapers

> Pfizer, which previously received a warning letter for the Meridian Medical Technologies plant that makes EpiPen injectors for Mylan, has reported to Health Canada that manufacturing problems have led to a shortage of the 0.3 mg format of the pen which it expects to have resolved by March 2, 2018. Release

> The FDA says that the shortage of saline has now led to a shortage of empty IV bags which healthcare providers have been using for compounded versions of the solution. Release

Whitepaper

Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

> Wuhan Chinese Moxibustion Technology Dev. Co., a maker of an updated version of a traditional Chinese medicine, has received an FDA warning letter for GMP failures at its plant in Wuhan, Hubei, China. Letter

Suggested Articles

Higher operating costs were behind a 17% slide in pretax profits last year at Allergan’s Mayo, Ireland, facility that produces Botox.

After a global scare over Zantac contamination, generic metformin could be next in line as regulators test for possible carcinogen contamination.

PCI Pharma Services debuts expansion of its plant in Rockford, Illinois.